Multi-target annular anti-microRNA antisense oligonucleotide, preparation method and application thereof, and multi-target drug

By designing multi-target circular antimicrobial antimicrobial oligonucleotides, using the circular structure of mutant bases and antisense oligonucleotide fragments, the problem of insufficient binding affinity for targeting multiple miRNAs in the prior art is solved. , effectively inhibiting multiple pathogenic miRNAs and protecting disease-resistant genes, significantly improving the therapeutic effect.

CN118910046APending Publication Date: 2024-11-08NUCLEAR CELL PHARMACEUTICAL R&D (GUANGZHOU) CO LTD

Patent Information

Application Number
CN202410960411.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing multi-target miRNA antisense nucleotide technology has the problem of insufficient binding affinity and stability when targeting multiple miRNAs. Moreover, the combination of multiple independent AMOs is complex and costly, making it difficult to effectively treat multifactorial and multi-mechanical treatments. disease.

Method used

Design a multi-target circular antimicrobial antimicrobial oligonucleotide by containing multiple target miRNA sense strand oligonucleotide fragments containing multiple target miRNAs and complete antisense oligonucleotide fragments containing multiple target miRNAs The phases are connected to form a loop, and the bases are complementary to form a double-stranded structure to inhibit miRNA.

Benefits of technology

Simultaneous inhibition of multiple critical pathogenic miRNAs is achieved, and the expression level and function of disease-resistant gene mRNAs is protected, which is significantly stronger than linear antisense oligonucleotide fragments of the same length, and is excellent in cardiovascular and tumor drug applications. inhibitory effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910046A_ABST
    Figure CN118910046A_ABST
Patent Text Reader

Abstract

The invention provides a multi-target annular anti-micro-RNA antisense oligonucleotide, a preparation method and application thereof, and a multi-target drug. The multi-target annular anti-micro-RNA antisense oligonucleotide is characterized in that a significance chain oligonucleotide fragment of a target miRNA containing a mutant basic group and a complete antisense oligonucleotide fragment of the target miRNA are alternately connected through linkers to form a ring; in the formed ring, the target miRNA significance chain oligonucleotide fragment containing the mutant basic group is further combined with the complete antisense oligonucleotide fragment of the target miRNA through basic group complementation to form double chains; a complete antisense oligonucleotide fragment of the target miRNA is contained in the ring, and a complete antisense oligonucleotide fragment of the same target miRNA is also carried outside the ring. The multi-target pharmacological drug effect is achieved, two or more target genes or miRNAs which play a key role in occurrence and development of diseases can be acted at the same time, and the stronger and more accurate effect is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine technology, and in particular to a multi-target circular anti-microRNA antisense oligonucleotide, a preparation method and application thereof, and a multi-target drug. Background Art

[0002] In cells, each mRNA may be a common target gene of multiple microRNAs (miRNAs), and will simultaneously pair and bind with these miRNAs and be inhibited by them, which is reflected in the inhibition of the translation of the target mRNA into the corresponding protein. At the same time, the target mRNA will also be degraded, so that its expression level and cell function are inhibited by these miRNAs.

[0003] Therefore, if a gene is a pathogenic gene for a certain disease, miRNA can be used to inhibit the expression and function of the gene, and these miRNAs can be regarded as anti-disease miRNAs; however, if the gene is a disease-resistant gene, it should be protected, and one of the strategies to protect the gene is to relieve the inhibitory effect of miRNA on it. The most commonly used relief approach is to use miRNA antisense nucleotides (AMO or antimiR or antagomiR) technology to knock down these miRNAs. However, knocking down only one of the many miRNAs that can inhibit a gene may maintain the inhibitory effect on the target mRNA due to the presence of other miRNAs; in other words, interfering with or knocking down any of the many miRNAs involved in inhibiting the same target mRNA is not enough to relieve the inhibitory effect on the target gene. This is a huge challenge we still face in targeting miRNA to relieve gene inhibition.

[0004] Prior art CN101121934B discloses "multi-target miRNA antisense nucleotide technology" (MT-AMO), wherein the designed multi-target miRNA antisense oligonucleotide is a linear fragment. Although it can simultaneously target multiple miRNAs and the target genes of these miRNAs, its affinity and stability for binding to the corresponding miRNAs are relatively weak. One of the reasons is that an oligonucleotide fragment containing multiple antisense nucleotide elements is usually more than 70nt in length. Even after sequence optimization, it is inevitable that there will be a self-folding structure, which affects its binding to microRNAs.

[0005] The existing technology also uses multiple independent miRNA antisense nucleotide fragments in combination, which can minimize the self-folding problem of MT-AMO, but it causes more problems in other aspects. For example, independent AMOs may form partial sequence complementarity to form a partial double-stranded structure, thereby hindering their binding to microRNA. More importantly, the pharmacokinetics of combined medication is more complicated, because each different AMO has its own unique pharmacokinetic process and characteristics, which makes clinical application quite complicated. In addition, the combination of multiple AMOs not only has a higher cost for clinical application, but also makes the research and development verification stage quite cumbersome and complicated. It can be seen that the combination of multiple independent AMOs may bring more problems than MT-AMO.

[0006] In addition, except for a very small number of diseases induced by single gene mutations, the vast majority of human diseases (especially chronic non-communicable diseases, such as cardiovascular and cerebrovascular diseases, cancer, lung, liver, kidney and other organ diseases, etc.) are multi-factor and multi-mechanism diseases. The results of drug development and clinical practice in the past few decades have warned us that the use of "single-target drugs" to interfere with only one of the multiple factors in the occurrence and development of a disease is often not enough to eliminate the root cause, because other causes still exist; on the contrary, "single-target drugs" often produce so-called off-target effects, that is, toxic side effects, which has led to many clinical drugs being withdrawn from the market and no longer used in clinical practice. For this reason, multi-target pharmacology came into being, and has become a new trend in new drug discovery or design in recent years, leading the direction of future drug development. The most fundamental essence of "multitarget drugs (MTDs)" is "one drug with multiple targets", and its most basic principle is "selective non-specificity", that is, an ideal drug should be able to selectively act on a group or several different factors that play a key role in a certain disease, and these factors refer to drug targets (such as several protein-encoding mRNAs). Specifically, if a disease is caused by the reduced expression level of several anti-disease mRNAs, then a good strategy to rescue these anti-disease mRNAs is to simultaneously target miRNAs that can inhibit these anti-disease mRNAs. To achieve this goal, we can apply the "multi-target miRNA antisense nucleotide technology" invented in the past as mentioned above or the combined use of multiple AMOs. However, as has been clearly pointed out above, these two technologies have their own shortcomings and may not be able to exert the disease treatment effect we expect. Therefore, this has also become another serious challenge faced by targeting miRNA to rescue mRNA in order to treat diseases.

[0007] In order to resolve the above two challenges at the same time, it is necessary to explore new technologies that can simultaneously target multiple miRNAs to rescue a certain disease-resistant gene mRNA, or simultaneously target multiple miRNAs to rescue multiple disease-related mRNAs, while also avoiding the weaknesses of the existing "multi-target miRNA antisense nucleotide technology" or the combination of multiple AMOs. Summary of the invention

[0008] The present application provides a multi-target circular anti-microRNA antisense oligonucleotide and a preparation method and application thereof to solve the problems existing in the related technologies. The technical solution is as follows:

[0009] In a first aspect, the embodiments of the present application provide a multi-target circular anti-microRNA antisense oligonucleotide, comprising a plurality of target miRNA sense chain oligonucleotide fragments containing mutant bases and a plurality of target miRNA complete antisense oligonucleotide fragments; the target miRNA sense chain oligonucleotide fragments containing mutant bases and the target miRNA complete antisense oligonucleotide fragments are alternately connected to form a ring through a linker;

[0010] In the formed loop, the target miRNA sense strand oligonucleotide fragment containing the mutant base is also combined with the complete antisense oligonucleotide fragment of the target miRNA to form a double strand through base complementarity.

[0011] In one embodiment, the sense strand oligonucleotide fragment of the target miRNA containing a mutant base contains 5-6 mutant bases relative to the sense strand oligonucleotide fragment of the target miRNA.

[0012] In one embodiment, the linker is a fragment of 4 bases.

[0013] In a second aspect, the present invention provides a method for preparing a multi-target circular anti-microRNA antisense oligonucleotide, comprising the following steps:

[0014] S1: Select multiple key miRNAs that can inhibit the expression of single or multiple target genes to obtain multiple target miRNAs;

[0015] S2: designing multiple sense oligonucleotide fragments of the target miRNA containing mutant bases according to the sequence of each target miRNA; and designing multiple complete antisense oligonucleotide fragments of the target miRNA;

[0016] S3: Using the base fragments as linkers, the sense strand oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA obtained in step S2 are alternately connected to form a single-stranded oligonucleotide fragment;

[0017] S4: cyclizing the single-stranded oligonucleotide fragment obtained in step S3 to prepare circular RNA;

[0018] S5: low-temperature annealing treatment is performed on the circular RNA obtained in step S4 and the complete antisense oligonucleotide fragment of the target miRNA designed in step S2 to obtain the multi-target circular anti-microRNA antisense oligonucleotide.

[0019] In one embodiment, when designing the sense strand oligonucleotide fragment of the target miRNA containing the mutant base in step S2, 5-6 bases of the sequence fragment of each target miRNA are mutated relative to the sequence of each target miRNA.

[0020] In one embodiment, in step S3, the base fragment serving as the linker is 4 bases.

[0021] In one embodiment, in step S4, the sense strand oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA are circularized using a "click circularization reaction" and connected alternately into a single-stranded oligonucleotide fragment.

[0022] In one embodiment, in step S5, the number of the complete antisense oligonucleotide fragments of the target miRNA is the same as or different from the number of the sense strand oligonucleotide fragments of the target miRNA containing the mutant base in the circular RNA.

[0023] In one embodiment, the number of the complete antisense oligonucleotide fragments of the target miRNA is the same as the number of the sense strand oligonucleotide fragments of the target miRNA containing the mutant base in the circular RNA.

[0024] In a third aspect, the embodiments of the present application provide an application of a multi-target circular anti-microRNA antisense oligonucleotide in the preparation of cardiovascular and tumor drugs.

[0025] In one embodiment, the tumor is breast cancer or pancreatic cancer.

[0026] In one embodiment, when it is breast cancer, the target miRNA is miR-10b-5p, miR-21-5p and miR-155-5p;

[0027] In one embodiment, the sense strand oligonucleotide fragments of the target miRNA containing the mutant bases are: miR-10b-5p mutant; miR-21-5p mutant and miR-155-5p mutant;

[0028] The sequence of the miR-10b-5p mutant is shown in SEQ ID NO.2; the sequence of the miR-21-5p mutant is shown in SEQ ID NO.5; and the sequence of the miR-155-5p mutant is shown in SEQ ID NO.8.

[0029] In one embodiment, the complete antisense oligonucleotide fragments of the target miRNA are: AMO-10b-5p, AMO-21-5p, and AMO-155-5p;

[0030] The sequence of AMO-10b-5p is shown in SEQ ID NO.3; the sequence of AMO-21-5p is shown in SEQ ID NO.6; and the sequence of AMO-155-5p is shown in SEQ ID NO.9.

[0031] In the case of pancreatic cancer, the target miRNAs are miR-21-5p, miR-155-5p and miR-221-5p.

[0032] In one embodiment, the sense strand oligonucleotide fragments of the target miRNA containing the mutant bases are: miR-21-5p mutant; miR-155-5p mutant; miR-221-5p mutant;

[0033] The sequence of the miR-21-5p mutant is shown in SEQ ID NO.5; the sequence of the miR-155-5p mutant is shown in SEQ ID NO.8; and the sequence of the miR-221-5p mutant is shown in SEQ ID NO.12.

[0034] In one embodiment, the complete antisense oligonucleotide fragments of the target miRNA are: AMO-21-5p; AMO-155-5p and AMO-221-5p;

[0035] The sequence of AMO-21-5p is shown in SEQ ID NO.6; the sequence of AMO-155-5p is shown in SEQ ID NO.9; and the sequence of AMO-221-5p is shown in SEQ ID NO.13.

[0036] In a fourth aspect, an embodiment of the present application provides a multi-target drug comprising any of the multi-target circular anti-microRNA antisense oligonucleotides described above.

[0037] The advantages or beneficial effects of the above technical solution include at least:

[0038] 1. A multi-target circular anti-microRNA antisense oligonucleotide of the present invention is composed of multiple target miRNA sense chain oligonucleotide fragments containing mutant bases and multiple target miRNA complete antisense oligonucleotide fragments connected alternately into a ring through a linker; the target miRNA sense chain oligonucleotide fragment containing mutant bases is also combined with the target miRNA complete antisense oligonucleotide fragment to form a double chain through base complementarity. Among them, the double-chain part is easy to fall off from the ring in the cell because of the incomplete pairing of the mutant gene on the target miRNA sense chain oligonucleotide fragment and the target miRNA complete antisense oligonucleotide fragment, so as to completely pair and combine with the target miRNA, thereby inhibiting the expression of the target miRNA; and the circular target miRNA complete antisense oligonucleotide fragment can also perform sponge adsorption with the target miRNA to inhibit the target miRNA. It can simultaneously inhibit multiple key pathogenic miRNAs and protect the expression levels and functional effects of multiple disease-resistant gene mRNAs (so that they are not inhibited by miRNA). In addition, the circular structure carries a larger number of completely antisense oligonucleotide fragments of the target miRNA, and its inhibitory effect on the target miRNA is significantly stronger than that of a linear antisense oligonucleotide fragment of the same length.

[0039] 2. A method for preparing a multi-target circular anti-microRNA antisense oligonucleotide of the present invention comprises introducing a mutant base into the designed target miRNA sense chain oligonucleotide fragment, and connecting it to the target miRNA complete antisense oligonucleotide fragment to form a ring through a linker, and then connecting the target miRNA complete antisense oligonucleotide fragment to the target miRNA sense chain oligonucleotide fragment in the ring through base pairing; this method obtains a multi-target circular anti-microRNA antisense oligonucleotide.

[0040] 3. The use of the multi-target circular anti-microRNA antisense oligonucleotides of the present invention in the preparation of cardiovascular and tumor drugs has an excellent inhibitory effect on miRNA, can protect and stimulate disease-resistant genes, and more effectively treat diseases.

[0041] The above summary is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments and features described above, further aspects, embodiments and features of the present application will be readily apparent by reference to the accompanying drawings and the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] In the accompanying drawings, unless otherwise specified, the same reference numerals throughout the multiple drawings represent the same or similar parts or elements. These drawings are not necessarily drawn to scale. It should be understood that these drawings only depict some embodiments disclosed in the present application and should not be regarded as limiting the scope of the present application.

[0043] Figure 1 A schematic diagram showing the conformation of the MT-circAMO construct targeting pancreatic cancer and the mechanism of action of the construct in delivering it into cells;

[0044] Figure 2 The figures are data effect diagrams of the relative knockdown effects of independent conventional AMOs, linear multi-target AMOs (MT-AMOs) and circular multi-target AMOs (MT-circAMOs) on their target miRNAs; (A) is a data effect diagram of the knockdown effects of various forms of AMOs on miR-10b-5p, miR-21-5p and miR-155-5p in the breast cancer cell line MDA-MB-453; (B) is a data effect diagram of the knockdown effects of various forms of AMOs on miR-21-5p, miR-155-5p and miR-221-5p in the pancreatic cancer cell line PANC-1;

[0045] Figure 3 The data effect diagram shows that independent conventional AMO, linear multi-target AMO (MT-AMO) and circular multi-target AMO (MT-circAMO) relieve the inhibition of their target miRNA on GFP fluorescent reporter gene;

[0046] Figure 4 The data are as follows: the relative inhibitory effects of independent conventional AMOs, linear multi-target AMOs (MT-AMOs), and circular multi-target AMOs (MT-circAMOs) on cancer cell viability, proliferation, migration, and invasion;

[0047] Figure 5 Effects of conventional AMO combination therapy, linear multi-targeted AMO (MT-AMO), and circular multi-targeted AMO (MT-circAMO) on xenograft tumors in female BALB / c nude mice approximately 4 to 6 weeks old. DETAILED DESCRIPTION

[0048] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present application. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature.

[0049] The present application embodiment provides a multi-target circular anti-microRNA antisense oligonucleotide (MT-circAMO), comprising a plurality of target miRNA sense chain oligonucleotide fragments containing mutant bases and a plurality of target miRNA complete antisense oligonucleotide fragments; the target miRNA sense chain oligonucleotide fragments containing mutant bases and the target miRNA complete antisense oligonucleotide fragments are alternately connected to form a ring through a linker;

[0050] In the formed loop, the target miRNA sense strand oligonucleotide fragment containing the mutant base and the target miRNA complete antisense oligonucleotide fragment are combined into a double strand through base complementarity.

[0051] According to the sequence characteristics of multiple different miRNAs that can inhibit one or more target gene mRNAs, a corresponding number of miRNA sense strand oligonucleotide fragments (sense strand) are designed. However, for each miRNA, a different base sequence needs to be introduced to obtain several miRNA fragments with "base mutations". At the same time, a complete antisense strand oligonucleotide fragment (antisense strand or AMO) of the corresponding miRNA is designed. Then, a linker or spacer is used to alternately link the sense strand fragments and antisense strands of these different miRNAs one by one to form a single-stranded oligonucleotide fragment. The oligonucleotide sequence of the sense strand and antisense strand is cyclized to form a circular RNA (artificially designed circular RNA or circRNA).

[0052] At the same time, a set of identical AMOs that are completely paired with the corresponding target miRNAs are synthesized based on the sequence of the target miRNA; finally, these free AMO fragments are incompletely base-paired with the corresponding miRNA sense chain regions carrying "mutations" in the circular RNA to form partially double-stranded circular RNA.

[0053] When this part of double-stranded circular RNA is delivered into cells (such as cardiomyocytes, cancer cells, etc.), the AMO fragment will fall off due to incomplete pairing with the circular RNA region, and will choose to bind to it because it is completely paired with the endogenous miRNA. At the same time, the antisense oligonucleotide fragment AMO contained in the circular RNA itself can also act as a sponge for miRNA (miRNA sponge); at the same time, the AMO sequence contained in the circular RNA itself is used to strongly inhibit miRNA.

[0054] It should be emphasized that in this embodiment, multiple target miRNAs containing mutant bases and multiple target miRNAs refer to multiple different miRNAs that can inhibit one or more target gene mRNAs. For the target disease, one or more of the most critical disease-resistant genes whose expression and function are inhibited by miRNAs are selected as target gene mRNAs, and multiple key miRNAs that can inhibit the expression of the selected single or multiple target gene mRNAs are selected; or several key pathogenic miRNAs can be directly selected as molecular targets based on existing knowledge.

[0055] In one embodiment, the sense chain oligonucleotide fragment of the target miRNA containing the mutant base contains 5-6 mutant bases relative to the sense chain oligonucleotide fragment of the target miRNA. The AMO forms an incompletely paired double-stranded structure with the ring, so that the ring carries the AMO; and in these incompletely paired double-stranded structures, the mutant base weakens the binding affinity of the AMO to the miRNA, so that in the cell, the difference in affinity between multiple AMOs and their corresponding target miRNAs and the mutant miRNA sequences contained in the circular RNA drives the AMO to break away from the circular RNA and bind to the endogenous target miRNA. Therefore, in view of the difference in affinity between the AMO and the ring and the AMO and the target miRNA, it is more appropriate to introduce 5-6 mutant bases into the sense chain oligonucleotide fragment of the miRNA. The position of the mutant base in the sense chain oligonucleotide fragment of the target miRNA is not specifically limited.

[0056] In one embodiment, the linker is a fragment of 4 bases. Preferably, the linker is ttat.

[0057] In one embodiment, the multi-target circular anti-microRNA antisense oligonucleotide is an anti-microRNA antisense oligonucleotide against breast cancer.

[0058] In this embodiment, the target miRNA is a miRNA that inhibits the expression of breast cancer tumor suppressor genes, and the miRNA is miR-10b-5p, miR-21-5p and miR-155-5p.

[0059] Therefore, the complete antisense oligonucleotide fragments of the multiple target miRNAs are respectively the complete antisense oligonucleotide fragments of miR-10b-5p, miR-21-5p and miR-155-5p; the sense chain oligonucleotide fragments of the target miRNA containing mutant bases are the sense chain oligonucleotide fragments of miR-10b-5p, miR-21-5p and miR-155-5p containing 5-6 base mutations;

[0060] In this embodiment, the target miRNAs miR-10b-5p (wild type), miR-21-5p (wild type) and miR-155-5p (wild type); multiple target miRNAs completely antisense oligonucleotide fragments miR-10b-5p (mutant), miR-21-5p (mutant) and miR-155-5p (mutant); multiple target miRNA sense chain oligonucleotide fragments AMO-10b-5p, AMO-21-5p and AMO-155-5p containing mutant bases are shown in Table 1:

[0061] Table 1

[0062]

[0063] Note: According to the WIPOST.26 standard, uracil "U" in the sequence in the table is represented by "T" in the sequence listing.

[0064] Therefore, in this embodiment, the sequence of the circular anti-microRNA antisense oligonucleotide for breast cancer multi-target is shown in SEQ ID NO.10:

[0065] SEQ ID NO.10:

[0066] UAUUCCGUAUAACAGAAUUCGUGttatCACAAAUUCGGUUCUACAGGGUAttatUAUGCUAUCAUCCUCAUGUUGAttatUCAACAUCAGUCUGAUAAGCUAttatUACAUACUAGUCCUGAUAUGGGUUttatAACCCCUAUCACGAUUAGCAUUAA.

[0067] Note: According to the WIPOST.26 standard, uracil "U" in the sequence is represented by "T" in the sequence table.

[0068] The head and tail ends of SEQ ID NO.10 are connected to form a loop; and the miR-10b-5p (mutant type) in the loop is paired with the AMO-10b-5p outside the loop to form a double-stranded structure; the miR-21-5p (mutant type) in the loop is paired with the AMO-21-5p outside the loop to form a double-stranded structure; the miR-155-5p (mutant type) in the loop is paired with the AMO-155-5p outside the loop to form a double-stranded structure.

[0069] In one embodiment, the multi-target circular anti-microRNA antisense oligonucleotide is an anti-microRNA antisense oligonucleotide against pancreatic cancer.

[0070] In this embodiment, the target miRNA is a miRNA that inhibits the expression of pancreatic cancer tumor suppressor genes, and the miRNA is miR-21-5p, miR-155-5p and miR-221-5p.

[0071] Therefore, the complete antisense oligonucleotide fragments of the multiple target miRNAs are respectively the complete antisense oligonucleotide fragments of miR-21-5p, miR-155-5p and miR-221-5p; the sense chain oligonucleotide fragments of the target miRNA containing mutant bases are the sense chain oligonucleotide fragments of miR-21-5p, miR-155-5p and miR-221-5p containing 5-6 base mutations;

[0072] In this embodiment, the target miRNAs miR-21-5p (wild type), miR-155-5p (wild type) and miR-221-5p (wild type); multiple target miRNAs completely antisense oligonucleotide fragments miR-21-5p (mutant type), miR-155-5p (mutant type) and miR-221-5p (mutant type); multiple target miRNA sense chain oligonucleotide fragments AMO-21-5p, AMO-155-5p and AMO-221-5p containing mutant bases are shown in Table 2:

[0073] Table 2

[0074]

[0075]

[0076] Note: According to the WIPOST.26 standard, uracil "U" in the sequence in the table is represented by "T" in the sequence listing.

[0077] Therefore, in this embodiment, the sequence of the multi-target circular anti-microRNA antisense oligonucleotide for pancreatic cancer is shown in SEQ ID NO.14:

[0078] SEQ ID NO.14:

[0079] UAUGCUAUCAUCCUCAUGUUGAttatUCAACAUCAGUCUGAUAAGCUAttatUACAUACUAGUCCUGAUAUGGGUUttatAACCCCUAUCACGAUUAGCAUUAAttatAGGUCGCAGACAAUGUACAUUUttatAAAUCUACAUUGUAUGCCAGGA.

[0080] Note: According to the WIPOST.26 standard, uracil "U" in the sequence is represented by "T" in the sequence table.

[0081] The head and tail ends of SEQ ID NO.14 are connected to form a loop; and the miR-21-5p (mutant type) in the loop is paired with the AMO-21-5p outside the loop to form a double-stranded structure; the miR-155-5p (mutant type) in the loop is paired with the AMO-155-5p outside the loop to form a double-stranded structure; the miR-221-5p (mutant type) in the loop is paired with the AMO-221-5p outside the loop to form a double-stranded structure.

[0082] In a second aspect, the present invention provides a method for preparing a multi-target circular anti-microRNA antisense oligonucleotide, comprising the following steps:

[0083] S1: Select multiple key miRNAs that can inhibit the expression of single or multiple target genes to obtain multiple target miRNAs;

[0084] In step S1, multiple key miRNAs that can inhibit the expression of single or multiple target genes are selected based on a certain target disease, such as a specific cardiovascular disease, cancer or other disease. According to existing knowledge, for the target disease, one or more of the most critical disease-resistant genes whose expression and function are inhibited by miRNA are selected as target gene mRNA. By inhibiting the expression of miRNA, the expression of the MRNA of the target gene of the disease-resistant gene whose expression and function are inhibited by one or more of the most critical is increased, thereby achieving a therapeutic effect. Of course, the present application can also directly select several key pathogenic miRNAs as molecular targets according to the target disease and existing knowledge; by inhibiting the expression of key pathogenic miRNAs, a therapeutic effect is achieved. In this embodiment, the number of multiple is not limited to a specific number, and in principle any number of key miRNAs can be obtained. According to the actual situation, it is appropriate for the number of multiple to be 2-5.

[0085] In this embodiment, multiple key miRNAs that inhibit the expression of single or multiple target genes are taken as an example.

[0086] S2: According to the sequence of each target miRNA, design multiple sense chain oligonucleotide fragments of the target miRNA containing mutant bases; and design multiple complete antisense oligonucleotide fragments of the target miRNA.

[0087] According to the sequences of these key miRNAs, a corresponding number of sense chain oligonucleotide fragments are designed, and artificial "base mutations" are introduced in each fragment, that is, base mismatches are paired with endogenous miRNAs. The corresponding number of sense chain oligonucleotide fragments means that the number of sense chain oligonucleotide fragments is consistent with the number of key miRNAs, and each key miRNA corresponds to a sense chain oligonucleotide fragment. Of course, the length of the sense chain oligonucleotide fragment should be the same as the length of the corresponding miRNA. The introduction of artificial "base mutations" in the fragments means that the designed sense chain oligonucleotide fragments have "base mutations" compared with the sequence of the key miRNA. This "base mutation" is introduced during the design process; its purpose is to weaken the binding affinity between the designed miRNA sense chain oligonucleotide fragment and the AMO to form a double-stranded structure, so that when encountering endogenous miRNA in the cell, the difference in affinity will drive the AMO to break away from the circular RNA and bind to the endogenous target miRNA, thereby achieving the purpose of inhibiting the expression of the target miRNA. AMOs are designed to inhibit target miRNAs by designing fully antisense oligonucleotide fragments of key miRNAs, so that the sequences of AMOs are complementary to those of key miRNAs.

[0088] In one embodiment, when designing a sense strand oligonucleotide fragment of a target miRNA containing a mutated base, 5-6 bases of the sequence fragment of each target miRNA are mutated relative to the sequence of each target miRNA.

[0089] S3: Using the base fragments as linkers, the sense strand oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA obtained in step S2 are alternately connected to form a single-stranded oligonucleotide fragment.

[0090] The designed sense chain oligonucleotide fragment of the target miRNA containing the mutant base and AMO are connected alternately to form a single-stranded oligonucleotide fragment using a linker or spacer. The base fragment used as the linker is 4 bases, but not limited to 4; when the base fragment used as the linker is 4 bases, the linker is "ttaa". The single-stranded oligonucleotide fragment is mainly prepared for the formation of a ring; the sense chain oligonucleotide fragment of the target miRNA containing the mutant base and AMO are connected alternately, and the subsequently formed ring has better stability.

[0091] In one embodiment, the fragment is directly synthesized using a RNA synthesizer (since the total length of the fragment exceeds 100 nt, the synthesizer has higher requirements), and purified using an ion exchange column to obtain a linear single-stranded oligonucleotide fragment.

[0092] In one embodiment, first, according to the designed MT-circAMO sequence, a linear DNA (deoxyribonucleic acid) fragment that is antisense to it is synthesized as a template for synthesizing RNA, and then transcribed and synthesized using an in vitro transcription kit to obtain a linear single-stranded oligonucleotide fragment. S4: The single-stranded oligonucleotide fragment obtained in step S3 is cyclized to prepare circular RNA.

[0093] Compared with chain-shaped RNA, partially double-stranded circular RNA of the same length can carry twice the number of AMO units as chain-shaped RNA, so its inhibitory effect on target miRNA is stronger.

[0094] In one embodiment, the sense oligonucleotide fragment of the target miRNA containing the mutated base and the complete antisense oligonucleotide fragment of the target miRNA are circularized using a "click circularization reaction" and connected alternately into a single-stranded oligonucleotide fragment.

[0095] In this embodiment, the specific method of "click cyclization reaction" is:

[0096] (1) During solid phase synthesis, 5-bromohexyl phosphoramidite is coupled to the 5' end of a linear single-stranded oligonucleotide chain to obtain a 5'-(5-bromohexyl) modified oligonucleotide;

[0097] (2) The 5'-(5-bromohexyl) modified oligonucleotide in step (1) is shaken and reacted with sodium azide and sodium iodide in anhydrous DMF solution; after the reaction is completed, the mixture is cooled to room temperature;

[0098] (3) solid-liquid separation, washing the CPG beads and the resulting 5'-(5-azidohexyl)-immobilized oligonucleotide with DMF; releasing the oligonucleotide from the solid support, and purifying and desalting;

[0099] (4) The oligonucleotide is then dissolved in water and subjected to a typical copper-catalyzed alkyne azide cycloaddition click cyclization reaction; the sense oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA are cyclized and connected alternately to form a single-stranded oligonucleotide fragment.

[0100] After the cyclization reaction, a purification step is also included:

[0101] The circular oligonucleotides were quickly purified using ion exchange HPLC purification and size exclusion HPLC desalting. After sterile filtration and freeze drying, the sense chain oligonucleotide fragments of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragments of the target miRNA were cyclized to a purity that met the high purity requirements required for in vivo experiments.

[0102] In this embodiment, in step (2), the molar ratio of the 5'-(5-bromohexyl) modified oligonucleotide, sodium azide and sodium iodide is 1:(100-300):(100-300); preferably, the molar ratio of the 5'-(5-bromohexyl) modified oligonucleotide, sodium azide and sodium iodide is 1:200:200. The concentration of the 5'-(5-bromohexyl) modified oligonucleotide is 0.5-1 μmol / ml; the reaction temperature is 55-70°C, and the reaction time is 30-120 min.

[0103] In this embodiment, the reaction conditions for a typical copper-catalyzed alkyne azide cycloaddition click cyclization reaction are:

[0104] Oligonucleotides were dissolved in water using a modified version of the protocol published by Lietard et al.: the oligonucleotide solution was mixed with methanol, sodium L-ascorbate, and copper sulfate solution; the reaction mixture was placed in a microwave tube container equipped with a stirring bar and placed in a microwave reactor at 60 °C for reaction.

[0105] In this embodiment, the oligonucleotide is dissolved in water to form a solution with a concentration of 10 OD260 units / ml; the volume ratio of the oligonucleotide solution to methanol is 1:1; the molar ratio of L-ascorbic acid sodium and copper sulfate added is 1:2; and the reaction temperature is 40 min.

[0106] Alternatively, the reaction is carried out at room temperature:

[0107] The linear oligonucleotide was suspended in a mixed solvent of methanol and water degassed with argon; a freshly prepared mixture of sodium L-ascorbate and copper sulfate in argon degassed water was added; the reaction was placed in a vial, sealed under argon, and then shaken at room temperature.

[0108] In this reaction, 0.9 ml of a 10 mg / ml linear oligonucleotide solution was suspended in 2.2 ml of a mixed solvent containing 9:2 methanol to water by volume; 0.25 ml of 0.1 mM sodium L-ascorbate and 0.25 ml of 20 mM copper sulfate were added. The best yield was obtained at about 4 h, with high conversion and minimal by-product formation; almost quantitative (>92.5%) conversion of the starting linear oligonucleotide.

[0109] S5: low-temperature annealing treatment is performed on the circular RNA obtained in step S4 and the complete antisense oligonucleotide fragment of the target miRNA designed in step S2 to obtain the multi-target circular anti-microRNA antisense oligonucleotide.

[0110] The purpose of step S5 is to continue to bind AMO on the formed circular RNA. Because there are sense strand oligonucleotide fragments of the target miRNA containing mutant bases in the circular RNA, although the sense strand oligonucleotide fragments of the target miRNA containing mutant bases contain mutant bases, they can still be incompletely paired with free AMO, and are combined together by base complementarity, so that the circular RNA forms a partially double-stranded circular RNA, whose inner ring contains the AMO sequence, and the outer ring also carries the same AMO. When this part of the double-stranded circular RNA is delivered into the cell (such as cardiomyocytes, cancer cells, etc.), the AMO fragments therein will fall off due to incomplete pairing with the region of the circular RNA, and at the same time, because they are completely paired with endogenous miRNA and choose to be combined with it, the antisense strand oligonucleotide fragment AMO contained in the circular RNA itself can also play a sponge adsorption effect (miRNAsponge) on miRNA. The dual action can strongly and effectively eliminate the effect of pathogenic key miRNA, and the expression and function of genes suppressed by these miRNAs are saved, thereby playing the effect of disease treatment.

[0111] In one embodiment, in step S5, the number of the complete antisense oligonucleotide fragments of the target miRNA is the same as or different from the number of the sense strand oligonucleotide fragments of the target miRNA containing the mutant base in the circular RNA.

[0112] In one embodiment, the number of the complete antisense oligonucleotide fragments of the target miRNA is the same as the number of the sense strand oligonucleotide fragments of the target miRNA containing the mutant base in the circular RNA.

[0113] The present application also provides an application of a multi-target circular anti-microRNA antisense oligonucleotide in the preparation of cardiovascular and tumor drugs.

[0114] In one embodiment, the tumor is breast cancer or pancreatic cancer.

[0115] In one embodiment, when it is breast cancer, the target miRNA is miR-10b-5p, miR-21-5p and miR-155-5p;

[0116] In the case of pancreatic cancer, the target miRNAs are miR-21-5p, miR-155-5p and miR-221-5p.

[0117] The embodiments of the present application provide a multi-target drug, comprising any of the multi-target circular anti-microRNA antisense oligonucleotides described above.

[0118] The following is a further description with reference to specific embodiments.

[0119] The present invention uses breast cancer and pancreatic cancer as target diseases. The reasons for choosing these two cancers are: (1) breast cancer is easy to target tumor tissues and is the most common cancer in women worldwide; (2) pancreatic cancer is a group of malignant tumors that mainly originate from the pancreatic ductal epithelium, i.e., acinar cells. It is highly malignant and has an insidious onset. It is difficult to diagnose in the early stages, progresses rapidly, is difficult to treat, has a short survival time (5-year survival rate is as low as 6%), and has an extremely poor prognosis. It is known as the "king of cancer". Its morbidity and mortality rates are both among the top ten malignant tumors in the world and my country.

[0120] Preparation of MT-circAMO targeting breast cancer

[0121] 1. Select multiple key miRNAs that can inhibit the expression of single or multiple target genes to obtain multiple target miRNAs:

[0122] The expression of miR-10b-5p, miR-21-5p, miR-155-5p and other "onco-miRNAs" in breast cancer cells is significantly upregulated, and they are involved in the occurrence and development of breast cancer. miR-10b enhances cancer cell migration and invasion by reducing the tumor suppressor gene HOXD10; the main target genes of miR-21 are the tumor suppressor genes PTEN, TIMP3 and PDCD4; the main target genes of miR-155 are the tumor suppressor genes TP53INP1 and SOCS1; miR-17-92 participates in cancer cell proliferation, apoptosis and tumor tissue angiogenesis by reducing the expression of tumor suppressor genes such as PTEN, p21, CCND1 and Bim. Using miRNA translation nucleotides to inhibit the expression of these miRNAs can produce the effect of inhibiting breast cancer; therefore, the present invention uses a combination of miR-10b-5p, miR-21-5p and miR-155-5p as a molecular target to verify the MT-circAMO technology in inhibiting breast cancer.

[0123] 2. According to the sequence of each target miRNA, design multiple target miRNA sense strand oligonucleotide fragments containing mutant bases; and design multiple target miRNA complete antisense oligonucleotide fragments:

[0124] According to the sequences of three key miRNAs in breast cancer, miR-10b-5p, miR-21-5p and miR-155-5p, the corresponding target miRNA sense chain oligonucleotide fragments (wild type) were designed, and six artificial "base mutations" were introduced into each fragment, i.e., six bases were mispaired with the endogenous miRNA, to obtain the target miRNA sense chain oligonucleotide fragments (mutant type) containing mutant bases, as shown in Table 1;

[0125] According to the sequences of three key miRNAs in breast cancer, miR-10b-5p, miR-21-5p and miR-155-p5, the corresponding antisense oligonucleotide fragments of the target miRNA, namely miRNA inhibitors (anti-miRNA antisense oligonucleotides or AMOs), were designed, as shown in Table 1.

[0126] 3. Use the base fragments as linkers to alternately connect the sense oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA into a single-stranded oligonucleotide fragment: Use a RNA synthesizer to directly synthesize, input the bases of the entire sequence into the instrument panel in order, and the instrument will synthesize according to the instructions, and then purify it through an ion exchange column to obtain a single-stranded oligonucleotide fragment:

[0127] Using a 4nt (four bases) fragment (ttat) as a linker, the designed "mutant" miRNA fragment and the AMO of the "wild-type" miRNA are alternately connected to form a single-stranded oligonucleotide fragment, the sequence of which is shown in SEQ ID NO.10;

[0128] SEQ ID NO.10:

[0129] 5'-UAUUCCGUAUAACAGAAUUCGUGttatCACAAAUUCGGUUCUACA GGGUAttatUAUGCUAUCAUCCUCAUGUUGAttatUCAACAUCAGUCUGAUA AGCUAttatUACAUACUAGUCCUGAUAUGGGUUttatAACCCCUAUCACGAU UAGCAUUAA-3'.

[0130] Note: According to the WIPOST.26 standard, uracil "U" in the sequence is represented by "T" in the sequence table.

[0131] 4. Circularize the single-stranded oligonucleotide fragment to prepare circular RNA:

[0132] Commercially available 5-bromohexyl phosphoramidite was coupled to the 5′ end of a linear single-stranded oligonucleotide chain during solid-phase synthesis;

[0133] A suspension of 10 μmol of CPG support loaded with 5'-(5-bromohexyl) modified oligonucleotide in 15 ml of anhydrous DMF solution containing 130 mg of sodium azide and 300 mg of sodium iodide was vigorously shaken at 65°C for 75 min. After cooling to room temperature, the solution was removed by filtration, and the CPG beads and the resulting 5'-(5-azidohexyl) immobilized oligonucleotide were washed with DMF (2 × 10 ml); the linear oligonucleotide was released from the solid support;

[0134] 0.9 mL of 9 mg of linear oligonucleotide was suspended in 1.8 ml of methanol and 0.4 ml of water, and the solvent was degassed with argon; 0.25 ml of a freshly prepared solution of 0.1 mM sodium L-ascorbate and 0.25 ml of 20 mM copper sulfate in argon-degassed water was added; the reactants were placed in a vial, sealed under argon, and then shaken at room temperature to obtain the best yield in about 4 hours, with high conversion and minimal by-product formation.

[0135] Ion exchange HPLC purification and size exclusion HPLC desalting and rapid purification of circular oligonucleotides to minimize copper complexation with the phosphate backbone; after sterile filtration and freeze drying, approximately 3 mg (30% isolation yield, comparable to conventional oligonucleotide synthesis and purification) of circular oligonucleotides (circRNA) were obtained, with a purity that met the high purity requirements required for in vivo experiments.

[0136] 5. The obtained circular RNA and the designed complete antisense oligonucleotide fragment of the target miRNA are subjected to low-temperature annealing treatment to obtain the multi-target circular anti-miRNA antisense oligonucleotide:

[0137] According to the designed complete antisense oligonucleotide fragment sequence of the target miRNA, AMO-10b-5p, AMO-21-5p and AMO-155-5p were synthesized respectively, and then annealed at low temperature with the prepared circRNA, so that these free AMOs were combined with the "mutant" sense strand sequence contained in the circRNA through base complementarity, thereby forming a partially double-stranded circular RNA, and obtaining a multi-target circular anti-microRNA antisense oligonucleotide (i.e. MT-circAMO for breast cancer). The inner ring of the circular MT-circAMO contains the AMO sequence, and the outer ring also carries the same AMO; a total of 6 AMO units targeting 3 different miRNAs are carried.

[0138] Preparation of MT-circAMO targeting pancreatic cancer

[0139] 1. Select multiple key miRNAs that can inhibit the expression of single or multiple target genes to obtain multiple target miRNAs:

[0140] The expression of miR-21-5p, miR-155-5p, miR-221-5p and other "onco-miRNAs" in breast cancer cells is significantly upregulated, and they are involved in the occurrence and development of pancreatic cancer. The main target genes of miR-21 are tumor suppressor genes PTEN, TIMP3 and PDCD4; the main target genes of miR-155 are tumor suppressor genes TP53INP1 and SOCS1; the main target genes of miR-221 are tumor suppressor genes CDKN1B, PDGF, p27Kip1 and TIMP-2. The upregulation of the expression of these three miRNAs can promote the proliferation, survival, migration, invasion and metastasis of pancreatic cancer cells by downregulating the expression of these tumor suppressor genes, thereby inducing and worsening pancreatic cancer. Inhibition of these miRNAs can inhibit pancreatic cancer; therefore, the present invention uses a combination of miR-21-5p, miR-155-5p and miR-221-5p as a molecular target to verify the MT-circAMO technology in inhibiting pancreatic cancer.

[0141] 2. According to the sequence of each target miRNA, design multiple target miRNA sense strand oligonucleotide fragments containing mutant bases; and design multiple target miRNA complete antisense oligonucleotide fragments:

[0142] According to the sequences of three key miRNAs of pancreatic cancer, miR-21-5p, miR-155-5p and miR-221-5p, the corresponding target miRNA sense chain oligonucleotide fragments (wild type) were designed, and six artificial "base mutations" were introduced into each fragment, i.e., six bases were mispaired with the endogenous miRNA, to obtain the target miRNA sense chain oligonucleotide fragments (mutant type) containing mutant bases, as shown in Table 2;

[0143] According to the sequences of three key miRNAs of pancreatic cancer, miR-21-5p, miR-155-5p and miR-221-5p, the corresponding antisense oligonucleotide fragments of the target miRNA, namely miRNA inhibitors (anti-miRNA antisense oligonucleotides or AMOs), were designed, as shown in Table 2.

[0144] 3. Using the base fragment as a linker, the sense oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA are alternately connected to form a single-stranded oligonucleotide fragment:

[0145] Using a 4nt (four bases) fragment (ttat) as a linker, the designed "mutant" miRNA fragment and the AMO of the "wild-type" miRNA are alternately connected to form a single-stranded oligonucleotide fragment, the sequence of which is shown in SEQ ID NO.14;

[0146] SEQ ID NO.14:

[0147] 5'-UAUGCUAUCAUCCUCAUGUUGAttatUCAACAUCAGUCUGAUAAG CUAttatUACAUACUAGUCCUGAUAUGGGUUttatAACCCCUAUCACGAUUA GCAUUAAttatAGGUCGCAGACAAUGUACAUUUttatAAAUCUACAUUGUAU GCCAGGA-3'.

[0148] Note: According to the WIPOST.26 standard, uracil "U" in the sequence is represented by "T" in the sequence table.

[0149] 4. Circularize the single-stranded oligonucleotide fragment to prepare circular RNA:

[0150] Commercially available 5-bromohexyl phosphoramidite was coupled to the 5′ end of a linear single-stranded oligonucleotide chain during solid-phase synthesis;

[0151] A suspension of 10 μmol of CPG support loaded with 5'-(5-bromohexyl) modified oligonucleotide in 15 ml of anhydrous DMF solution containing 130 mg of sodium azide and 300 mg of sodium iodide was vigorously shaken at 65°C for 75 min. After cooling to room temperature, the solution was removed by filtration, and the CPG beads and the resulting 5'-(5-azidohexyl) immobilized oligonucleotide were washed with DMF (2 × 10 ml); the linear oligonucleotide was released from the solid support;

[0152] 0.9 mL of 9 mg of linear oligonucleotide was suspended in 1.8 ml of methanol and 0.4 ml of water, and the solvent was degassed with argon; 0.25 ml of a freshly prepared solution of 0.1 mM sodium L-ascorbate and 0.25 ml of 20 mM copper sulfate in argon-degassed water was added; the reactants were placed in a vial, sealed under argon, and then shaken at room temperature to obtain the best yield in about 4 hours, with high conversion and minimal by-product formation.

[0153] Ion exchange HPLC purification and size exclusion HPLC desalting and rapid purification of circular oligonucleotides to minimize copper complexation with the phosphate backbone; after sterile filtration and freeze drying, approximately 3 mg (30% isolation yield, comparable to conventional oligonucleotide synthesis and purification) of circular oligonucleotides (circRNA) were obtained, with a purity that met the high purity requirements required for in vivo experiments.

[0154] 5. The obtained circular RNA and the designed complete antisense oligonucleotide fragment of the target miRNA are subjected to low-temperature annealing treatment to obtain the multi-target circular anti-miRNA antisense oligonucleotide:

[0155] According to the designed complete antisense oligonucleotide fragment sequence of the target miRNA, AMO-21-5p, AMO-155-5p and AMO-221-5p were synthesized respectively, and then annealed at low temperature together with the prepared circRNA, so that these free AMOs were combined with the "mutant" sense strand sequence contained in the circRNA one by one through base complementarity, thereby forming a partially double-stranded circular RNA, and obtaining a multi-target circular anti-microRNA antisense oligonucleotide (i.e. MT-circAMO for pancreatic cancer). The structural diagram is shown in the figure below. Figure 1 shown.

[0156] from Figure 1 It can be seen that the inner ring of the circular MT-circAMO contains the AMO sequence, and the outer ring also carries the same AMO; a total of 6 AMO units targeting 3 different miRNAs are carried.

[0157] 3. Negative Control and Comparative Ratio

[0158] Negative control circRNA: According to the above preparation method, a circRNA consisting of 6 negative control nucleotide fragments (5'-ACUUACGAGUGACAGUAGA-3') connected in pairs by a 4nt linker (ttat) was synthesized as the negative control sequence of MT-circAMO.

[0159] Linear MT-AMO:

[0160] A linear multi-target nucleotide sequence MT-AMO (miR-10+miR-21+miR-155) for breast cancer was synthesized; the sequence is shown in SEQ ID NO.15:

[0161] SEQ ID NO.15:

[0162] 5'-CACAAAUUCGGUUCUACAGGGUAttatUCAACAUCAGUCUGAUAA GCUAttatAACCCCUAUCACGAUUAGCAUUAA-3';

[0163] Note: According to the WIPOST.26 standard, uracil "U" in the sequence is represented by "T" in the sequence table.

[0164] A linear multi-target nucleotide sequence MT-AMO (miR-21+miR-155+miR-221) targeting pancreatic cancer was synthesized; the sequence is shown in SEQ ID NO.16:

[0165] SEQ ID NO.16:

[0166] 5'-UCAACAUCAGUCUGAUAAGCUAttatAACCCCUAUCACGAUUAGCAUUAAttatAAAUCUACAUUGUAUGCCAGGA-3'.

[0167] Note: According to the WIPOST.26 standard, uracil "U" in the sequence is represented by "T" in the sequence table.

[0168] Regular AMO:

[0169] Conventional AMOs for breast cancer: AMO-10b-5p, AMO-21-5p, and AMO-155-5p;

[0170] Conventional AMOs for pancreatic cancer: AMO-21-5p, AMO-155-5p, and AMO-221-5p.

[0171] IV. Examples of multi-target circular anti-microRNA antisense oligonucleotides for cancer treatment:

[0172] (1) Two human breast cancer cell lines, MDA-MB-453 (triple-negative adenocarcinoma, metastatic) and SK-BR-3 (double-negative double-positive adenocarcinoma, metastatic) and two human pancreatic cancer cell lines, PANC-1 (pancreatic head cancer, metastatic) and MIA-PaCa-2 (pancreatic tail carcinoma in situ, infiltrating around the aorta), were selected. MT-circAMO targeting breast cancer and MT-circAMO targeting pancreatic cancer as well as negative control circRNA were transfected into the above cell lines using lipid lipofectamine. Then, real-time RT-PCR was used to detect changes in the expression levels of miR-10b-5p, miR-21-5p, miR-155-5p and miR-221-5p. The expression results are shown in Figure 2. Figure 2 As shown:

[0173] Experimental data revealed that MT-circAMO significantly downregulated the levels of these "proto-oncogene" miRNAs, with an inhibition rate between 80% and 90%, which is much greater than the inhibitory effect produced by the co-transfection of conventional linear MT-AMO of AMO-10b-5p+AMO-21-5p+AMO-155-5p and linear MT-AMO of AMO-21-5p+AMO-155-5p+AMO-221-5p (40%-57%).

[0174] Linear MT-AMO is a linear antisense oligonucleotide fragment formed by several AMOs connected by linkers, while circular MT-circAMO is an antisense oligonucleotide sequence formed by several unlinked AMOs carried by specially designed circular RNA. Therefore, the former may form its own secondary structure (such as a hairpin structure), affecting its anti-miRNA effect, while MT-circAMO does not have the problem of sequence self-folding; the number of AMOs that can be contained in linear MT-AMO is limited, and the possibility of forming its own secondary folding structure is also large if the sequence is too long, and the efficacy may be limited. In contrast, the number of AMO units that can be carried by partially double-stranded circular MT-circAMO of the same length is twice that of MT-AMO. Therefore, the inhibitory effect of circular MT-circAMO on target miRNA must be stronger than that of linear MT-AMO.

[0175] (2) Using a dual luciferase reporter gene assay carrying miRNA action site sequences, we compared and verified the efficacy of MT-circAMO, conventional AMO, and linear MT-AMO in inhibiting the function of the corresponding miRNA;

[0176] The comparison verification process is as follows:

[0177] An oligonucleotide fragment containing the action site sequence of miR-10b-5p, miR-21-5p, miR-155-5p and miR-221-5p (i.e., the seed site, i.e., the sequence that pairs with these miRNAs) was cloned and inserted into the luciferase reporter gene vector pMIR-REPORT;

[0178] pMIR-REPORT was transfected into a group of HEK293 cells as the control group, and pMIR-REPORT was co-transfected with miR-10b-5p, miR-21-5p, miR-155-5p and miR-221-5p into HEK293 cells as the experimental group; then the luciferase activity was measured respectively. The luciferase activity of the experimental group decreased compared with the control group, indicating that miR-10b-5p, miR-21-5p, miR-155-5p and miR-221-5p can act on their respective target sequences;

[0179] pMIR-REPORT was transfected into a group of HEK293 cells as a control group, and pMIR-REPORT was co-transfected with miR-10b-5p, miR-21-5p, miR-155-5p, miR-221-5p, MT-circAMO, linear MT-AMO, or conventional AMO into HEK293 cells as an experimental group. Then the luciferase activity was measured respectively. It was found that after transfection with different forms of AMO, the luciferase activity showed different degrees of recovery compared with that after transfection with miRNA alone, proving that AMO effectively inhibited the function of miRNA, thereby restoring luciferase activity.

[0180] In order to verify the inhibitory effect of different forms of AMO on the corresponding endogenous miRNA, that is, to relieve the inhibitory effect of endogenous miRNA on its target gene, pMIR-REPORT was transfected into a group of HEK293 cells as a control group, and pMIR-REPORT was co-transfected with MT-circAMO or linear MT-AMO or conventional AMO into HEK293 cells as several experimental groups; luciferase activity was measured respectively. The results are shown in Figure 3 As shown,

[0181] Figure 3 The results showed that the luciferase activity in the experimental group increased to varying degrees compared with the control group, proving that MT-circAMO, linear MT-AMO and conventional AMO relieved the inhibitory effects of endogenous miRNA on their target genes to varying degrees. Moreover, the "multi-target circular anti-microRNA antisense oligonucleotide" MT-circAMO showed effective relief of the inhibitory effects of three miRNAs on the GFP fluorescent reporter gene, and its effect strength was 3 times greater than that of conventional AMO and linear MT-AMO.

[0182] (3) Verification of the effect of MT-circAMO on killing breast cancer and pancreatic cancer cells at the cellular level

[0183] The survival rate of cancer cells was detected by CCK-8 kit, and the specific steps were carried out in full accordance with the steps provided in the kit (supplier: APExBIO, USA); the proliferation ability of cancer cells was detected by EdU Assay / EdU Staining Proliferation Kit (iFluor 488) kit from Abcam China, and the specific steps were carried out in full accordance with the steps provided in the kit; the migration and invasion ability of cancer cells was detected by cell migration and invasion assay staining kit (Beijing Solebow Technology Co., Ltd.), and the specific steps were carried out in full accordance with the steps provided in the kit. Of course, the kits in this part can also be replaced by kits from other suppliers; the results are shown in Figure 4 As shown:

[0184] from Figure 4 From the results, we can see that MT-circAMO is much more effective than conventional linear MT-AMO and conventional AMO in killing breast cancer and pancreatic cancer cells and inhibiting the proliferation and metastasis of these cancer cells. The proliferation inhibition rate of MT-circAMO on breast cancer and pancreatic cancer cells is as high as 88%-94%, while the inhibition rate of linear MT-AMO is 48%-68%, and the conventional AMO alone is only 27%-42%; the inhibition rate of MT-circAMO on the migration of breast cancer and pancreatic cancer cells is as high as 92%-100%, while the inhibition rate of linear MT-AMO on migration is 55%-65%, and the conventional AMO alone is only 33%-53%.

[0185] (4) In vivo experiments in immunodeficient mice

[0186] Using breast cancer and pancreatic cancer xenograft (CDX) models, the above two human breast cancer cells and two pancreatic cancer cell lines were subcutaneously inoculated into immunodeficient mice. The cultured cell inoculation method was used: the cancer cells in the logarithmic growth phase were digested and decellularized with 0.25% trypsin, and then centrifuged at 1000r / min with PBS for 10 minutes, washed twice, the trypsin in the cells and the serum and other components in the culture medium were washed away, the number of live cells was counted with trypan blue staining, and the tumor was made into a cell suspension of a certain concentration with PBS. 0.2mL of tumor cell fluid (containing 1×10 6 --1×10 7 cells).

[0187] The anti-tumor activity and efficacy of the two MT-circAMOs were evaluated in breast cancer transplant tumor models and pancreatic cancer transplant tumor models, respectively. The evaluation indicators included tumor volume, animal weight, and tumor weight at the end of the experiment. The specific method is to directly inject the MT-circAMO solution treated with lipofectamine into the tumor once after the tumor grows (about 7 days after inoculation) (the control group is injected with the control sequence), and the tumor volume is measured every other day; the experiment is terminated four weeks after inoculation, the animals are killed, and the liver, kidney, lung, and intestinal tissues are quickly removed to detect tumor metastasis, and then the tumor mass is peeled off and weighed. The relative tumor proliferation rate, tumor growth curve, tumor growth inhibition rate, animal weight and mortality rate are calculated based on the changes in tumor volume. The results are as follows Figure 5 As shown:

[0188] The results showed that the two MT-circAMOs exerted a strong inhibitory effect on breast cancer xenograft models and pancreatic cancer xenografts, respectively. The tumor volume was reduced by 88% and 82% relative to the negative circRNA control group, while the linear MT-AMO only reduced the volume by 51% and 46%, and the combination of conventional AMOs only produced a 26%-35% effect; the tumor proliferation rate was reduced by 85% and 79% by MT-circAMO, by 47% and 41% by linear MT-AMO, and by 18%-22% by the combination of conventional AMOs; MT-circAMO tumor inhibition The rates were as high as 93% and 90% respectively, linear MT-AMO reached 55% and 49%, while the combination of conventional AMO reached only 21%-24%; MT-circAMO had no significant effect on animal body weight, the body weight of animals treated with linear MT-AMO decreased by 23%, the combination of conventional AMO decreased by 34%, and the negative control circRNA decreased by 46%; the mortality rate of the negative control circRNA group was 20% (2 / 10), the combination of conventional AMO was 10% (1 / 10), and the linear MT-AMO and MT-circAMO were 0% (0 / 10).

[0189] Mice treated with MT-circAMO showed no obvious visceral tissue metastasis, mice treated with MT-AMO showed mild metastasis in the liver, the conventional AMO combination group had moderate liver and intestinal cancer cell metastasis, and the negative control circRNA group showed obvious liver, lung, and intestinal cancer cell metastasis.

[0190] In the present invention, the above-mentioned design and implementation for breast cancer and pancreatic cancer are only used as examples. Using the principles, methods and steps of multi-target circular anti-microRNA antisense oligonucleotide (MT-circAMO) technology, countless nucleic acid drugs can be designed and prepared in theory, and developed into clinical drugs. MT-circAMO acid drugs can be used to simultaneously inhibit multiple key pathogenic miRNAs and protect the expression levels and functional effects of multiple disease-resistant gene mRNAs (so that they are not inhibited by miRNAs).

[0191] In summary, MT-circAMO integrates multiple miRNA antisense nucleotide inhibitor "drug" AMOs into one, which is superior to single-target drug independent AMOs in terms of pharmacodynamics, and can more thoroughly inhibit the protection of "onco-miRNA" and stimulate disease-resistant genes, thereby more effectively treating diseases; in terms of pharmacokinetics, it must be superior to the combination drug strategy of several independent AMOs. In terms of industrial-scale production, the pharmaceutical cost of using MT-circAMO technology is much lower than the combination drug strategy of using several single-target AMOs. In clinical applications, a multi-target therapeutic drug can make patients more compliant with medication than the combination of multiple single-target drugs.

[0192] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.

[0193] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of this application, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.

[0194] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any technician familiar with the technical field can easily think of various changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.

Claims

1. A multi-target circular anti-microRNA antisense oligonucleotide, characterized in that: The method comprises a plurality of target miRNA sense chain oligonucleotide fragments containing mutant bases and a plurality of target miRNA complete antisense oligonucleotide fragments; the target miRNA sense chain oligonucleotide fragments containing mutant bases and the target miRNA complete antisense oligonucleotide fragments are alternately connected to form a ring through a linker; In the formed loop, the target miRNA sense strand oligonucleotide fragment containing the mutant base is also combined with the complete antisense oligonucleotide fragment of the target miRNA to form a double strand through base complementarity.

2. A multi-target circular anti-microRNA antisense oligonucleotide according to claim 1, characterized in that: The sense strand oligonucleotide fragment of the target miRNA containing a mutant base contains 5-6 mutant bases relative to the sense strand oligonucleotide fragment of the target miRNA.

3. A multi-target circular anti-microRNA antisense oligonucleotide according to claim 1, characterized in that The linker is a fragment of 4 bases.

4. A method for preparing a multi-target circular anti-microRNA antisense oligonucleotide, characterized in that: The following steps are involved: S1: Select multiple key miRNAs that can inhibit the expression of single or multiple target genes to obtain multiple target miRNAs; S2: designing multiple sense oligonucleotide fragments of the target miRNA containing mutant bases according to the sequence of each target miRNA; and designing multiple complete antisense oligonucleotide fragments of the target miRNA; S3: Using the base fragments as linkers, the sense strand oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA obtained in step S2 are alternately connected to form a single-stranded oligonucleotide fragment; S4: cyclizing the single-stranded oligonucleotide fragment obtained in step S3 to prepare circular RNA; S5: low-temperature annealing treatment is performed on the circular RNA obtained in step S4 and the complete antisense oligonucleotide fragment of the target miRNA designed in step S2 to obtain the multi-target circular anti-microRNA antisense oligonucleotide.

5. The method for preparing a multi-target circular anti-microRNA antisense oligonucleotide according to claim 4, characterized in that: When designing the sense strand oligonucleotide fragment of the target miRNA containing the mutant base in step S2, 5-6 bases of the sequence fragment of each target miRNA are mutated relative to the sequence of each target miRNA; In step S3, the base fragment used as the linker is 4 bases; In step S4, the sense strand oligonucleotide fragment of the target miRNA containing the mutant base and the complete antisense oligonucleotide fragment of the target miRNA are circularized using a "click cyclization reaction" and connected alternately into a single-stranded oligonucleotide fragment.

6. The method for preparing a multi-target circular anti-microRNA antisense oligonucleotide according to claim 4, characterized in that: In step S5, the number of complete antisense oligonucleotide fragments of the target miRNA is the same as or different from the number of sense chain oligonucleotide fragments of the target miRNA containing mutant bases in the circular RNA; preferably, the number of complete antisense oligonucleotide fragments of the target miRNA is the same as the number of sense chain oligonucleotide fragments of the target miRNA containing mutant bases in the circular RNA.

7. Use of a multi-target circular anti-microRNA antisense oligonucleotide according to any one of claims 1 to 6 in the preparation of cardiovascular and tumor drugs.

8. Use of a multi-target circular anti-microRNA antisense oligonucleotide according to claim 7 in the preparation of cardiovascular and tumor drugs, characterized in that: The tumor is breast cancer or pancreatic cancer.

9. Use of a multi-target circular anti-microRNA antisense oligonucleotide according to claim 8 in the preparation of an anti-tumor drug, characterized in that: When it is breast cancer, the target miRNA is miR-10b-5p, miR-21-5p and miR-155-5p; The sense strand oligonucleotide fragments of the target miRNA containing the mutant bases are: miR-10b-5p mutant; miR-21-5p mutant and miR-155-5p mutant; The sequence of the miR-10b-5p mutant is shown in SEQ ID NO. 2; The sequence of the miR-21-5p mutant is shown in SEQ ID NO.5; the sequence of the miR-155-5p mutant is shown in SEQ ID NO.8; The complete antisense oligonucleotide fragments of the target miRNAs are: AMO-10b-5p, AMO-21-5p, and AMO-155-5p; The sequence of AMO-10b-5p is shown in SEQ ID NO.3; the sequence of AMO-21-5p is shown in SEQ ID NO.6; the sequence of AMO-155-5p is shown in SEQ ID NO.9; When it is pancreatic cancer, the target miRNA is miR-21-5p, miR-155-5p and miR-221-5p; The sense strand oligonucleotide fragments of the target miRNA containing the mutant bases are: miR-21-5p mutant, miR-155-5p mutant, and miR-221-5p mutant; The sequence of the miR-21-5p mutant is shown in SEQ ID NO.5; the sequence of the miR-155-5p mutant is shown in SEQ ID NO.8; the sequence of the miR-221-5p mutant is shown in SEQ ID NO.12; The complete antisense oligonucleotide fragments of the target miRNA are: AMO-21-5p; AMO-155-5p and AMO-221-5p; The sequence of AMO-21-5p is shown in SEQ ID NO.6; the sequence of AMO-155-5p is shown in SEQ ID NO.9; and the sequence of AMO-221-5p is shown in SEQ ID NO.

13.

10. A multi-target drug, characterized in that: A multi-target circular anti-microRNA antisense oligonucleotide comprising any one of claims 1-6.

Citation Information

Patent Citations

  • Preparation method of antisense nucleotides of multi-target miRNA

    CN101121934B

Cited By

  • Small nucleic acid composition, application of small nucleic acid composition in preparation of medicine and product

    CN119552871A